Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Receivables (2016 - 2025)

Historic Receivables for Myriad Genetics (MYGN) over the last 16 years, with Q3 2025 value amounting to $118.0 million.

  • Myriad Genetics' Receivables fell 612.57% to $118.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $118.0 million, marking a year-over-year decrease of 612.57%. This contributed to the annual value of $121.2 million for FY2024, which is 603.67% up from last year.
  • Myriad Genetics' Receivables amounted to $118.0 million in Q3 2025, which was down 612.57% from $137.0 million recorded in Q2 2025.
  • Myriad Genetics' Receivables' 5-year high stood at $137.0 million during Q2 2025, with a 5-year trough of $91.3 million in Q4 2021.
  • Over the past 5 years, Myriad Genetics' median Receivables value was $114.3 million (recorded in 2023), while the average stood at $111.1 million.
  • The largest annual percentage gain for Myriad Genetics' Receivables in the last 5 years was 3352.11% (2021), contrasted with its biggest fall of 809.52% (2021).
  • Quarter analysis of 5 years shows Myriad Genetics' Receivables stood at $91.3 million in 2021, then increased by 11.28% to $101.6 million in 2022, then rose by 12.5% to $114.3 million in 2023, then increased by 6.04% to $121.2 million in 2024, then fell by 2.64% to $118.0 million in 2025.
  • Its Receivables was $118.0 million in Q3 2025, compared to $137.0 million in Q2 2025 and $120.4 million in Q1 2025.